Signaling pathways in cranial chondrosarcoma: Potential molecular targets for directed chemotherapy

Orin Bloch, Michael E. Sughrue, Steven A. Mills, Andrew T. Parsa

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Cranial chondrosarcoma is an indolent tumor of the skull base, which is difficult to treat due to its inaccessible location. The current mainstay of treatment is surgical resection followed by adjuvant radiation therapy. To date, chemotherapy has been largely ineffective for chondrosarcoma due to a lack of targeted therapies. This review highlights numerous active signaling pathways that have been described in human chondrosarcoma. A limited number of functional experiments suggest that integrin activation at the cell surface results in upregulation of matrix metalloproteinases and extracellular matrix degradation, leading to increased tumor cell migration. This pathway appears to be dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling. Additionally, chondrosarcoma cell proliferation and degradation is dependent on peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity, with a loss of PPAR-γ expression and associated apoptosis in high-grade tumors. The data suggest that targeting these pathways may improve control of cranial chondrosarcoma and decrease the need for hazardous recurrent operations.

Original languageEnglish (US)
Pages (from-to)881-885
Number of pages5
JournalJournal of Clinical Neuroscience
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2011
Externally publishedYes

Fingerprint

Chondrosarcoma
Drug Therapy
PPAR gamma
Neoplasms
1-Phosphatidylinositol 4-Kinase
Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Skull Base
Matrix Metalloproteinases
Integrins
Cell Movement
Extracellular Matrix
Up-Regulation
Radiotherapy
Cell Proliferation
Apoptosis
Therapeutics

Keywords

  • Cranial chondrosarcoma
  • Integrin αvβ3
  • Matrix metalloproteinase
  • PI3K pathway
  • PPAR-γ

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Signaling pathways in cranial chondrosarcoma : Potential molecular targets for directed chemotherapy. / Bloch, Orin; Sughrue, Michael E.; Mills, Steven A.; Parsa, Andrew T.

In: Journal of Clinical Neuroscience, Vol. 18, No. 7, 01.07.2011, p. 881-885.

Research output: Contribution to journalReview article

Bloch, Orin ; Sughrue, Michael E. ; Mills, Steven A. ; Parsa, Andrew T. / Signaling pathways in cranial chondrosarcoma : Potential molecular targets for directed chemotherapy. In: Journal of Clinical Neuroscience. 2011 ; Vol. 18, No. 7. pp. 881-885.
@article{7a30fcfdcaad49fbb336bb77c699ea49,
title = "Signaling pathways in cranial chondrosarcoma: Potential molecular targets for directed chemotherapy",
abstract = "Cranial chondrosarcoma is an indolent tumor of the skull base, which is difficult to treat due to its inaccessible location. The current mainstay of treatment is surgical resection followed by adjuvant radiation therapy. To date, chemotherapy has been largely ineffective for chondrosarcoma due to a lack of targeted therapies. This review highlights numerous active signaling pathways that have been described in human chondrosarcoma. A limited number of functional experiments suggest that integrin activation at the cell surface results in upregulation of matrix metalloproteinases and extracellular matrix degradation, leading to increased tumor cell migration. This pathway appears to be dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling. Additionally, chondrosarcoma cell proliferation and degradation is dependent on peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity, with a loss of PPAR-γ expression and associated apoptosis in high-grade tumors. The data suggest that targeting these pathways may improve control of cranial chondrosarcoma and decrease the need for hazardous recurrent operations.",
keywords = "Cranial chondrosarcoma, Integrin αvβ3, Matrix metalloproteinase, PI3K pathway, PPAR-γ",
author = "Orin Bloch and Sughrue, {Michael E.} and Mills, {Steven A.} and Parsa, {Andrew T.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.jocn.2010.09.025",
language = "English (US)",
volume = "18",
pages = "881--885",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "7",

}

TY - JOUR

T1 - Signaling pathways in cranial chondrosarcoma

T2 - Potential molecular targets for directed chemotherapy

AU - Bloch, Orin

AU - Sughrue, Michael E.

AU - Mills, Steven A.

AU - Parsa, Andrew T.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Cranial chondrosarcoma is an indolent tumor of the skull base, which is difficult to treat due to its inaccessible location. The current mainstay of treatment is surgical resection followed by adjuvant radiation therapy. To date, chemotherapy has been largely ineffective for chondrosarcoma due to a lack of targeted therapies. This review highlights numerous active signaling pathways that have been described in human chondrosarcoma. A limited number of functional experiments suggest that integrin activation at the cell surface results in upregulation of matrix metalloproteinases and extracellular matrix degradation, leading to increased tumor cell migration. This pathway appears to be dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling. Additionally, chondrosarcoma cell proliferation and degradation is dependent on peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity, with a loss of PPAR-γ expression and associated apoptosis in high-grade tumors. The data suggest that targeting these pathways may improve control of cranial chondrosarcoma and decrease the need for hazardous recurrent operations.

AB - Cranial chondrosarcoma is an indolent tumor of the skull base, which is difficult to treat due to its inaccessible location. The current mainstay of treatment is surgical resection followed by adjuvant radiation therapy. To date, chemotherapy has been largely ineffective for chondrosarcoma due to a lack of targeted therapies. This review highlights numerous active signaling pathways that have been described in human chondrosarcoma. A limited number of functional experiments suggest that integrin activation at the cell surface results in upregulation of matrix metalloproteinases and extracellular matrix degradation, leading to increased tumor cell migration. This pathway appears to be dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling. Additionally, chondrosarcoma cell proliferation and degradation is dependent on peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity, with a loss of PPAR-γ expression and associated apoptosis in high-grade tumors. The data suggest that targeting these pathways may improve control of cranial chondrosarcoma and decrease the need for hazardous recurrent operations.

KW - Cranial chondrosarcoma

KW - Integrin αvβ3

KW - Matrix metalloproteinase

KW - PI3K pathway

KW - PPAR-γ

UR - http://www.scopus.com/inward/record.url?scp=79958087748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958087748&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2010.09.025

DO - 10.1016/j.jocn.2010.09.025

M3 - Review article

C2 - 21640907

AN - SCOPUS:79958087748

VL - 18

SP - 881

EP - 885

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 7

ER -